Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 2:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Bavituximab Clear all
Completed Phase 2 Interventional Results available

A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma

NCT03519997
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Pembrolizumab, Bavituximab
Drug
Lead sponsor
David Hsieh
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 19, 2026, 2:32 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer

NCT01335204
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasms
Interventions
Cabazitaxel plus bavituximab
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2018 · Synced Oct 19, 2026, 2:32 PM EDT
Completed Phase 1 Interventional

Repeat-Dose Study of Bavituximab in Patients With Chronic Hepatitis C

NCT00343525
View directory record Official record
Conditions
Hepatitis C
Interventions
bavituximab
Drug
Lead sponsor
Peregrine Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Sarasota, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2008 · Synced Oct 19, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Results available

Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma

NCT03139916
View directory record Official record
Conditions
Glioblastoma
Interventions
Temozolomide, Bavituximab, Radiation
Drug · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 19, 2026, 2:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer

NCT01264705
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Cancer
Interventions
bavituximab (0.3 mg/kg) and sorafenib, bavituximab (1.0 mg/kg ) and sorafenib, bavituximab (3.0 mg/kg) and sorafenib
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Oct 19, 2026, 2:32 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer

NCT02651610
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Bavituximab, Taxane
Biological · Drug
Lead sponsor
Peregrine Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Bakersfield, California • Tinley Park, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 19, 2026, 2:32 PM EDT
Active, not recruiting Phase 2 Interventional Results available

1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck

NCT04150900
View directory record Official record
Conditions
Squamous Cell Carcinoma
Interventions
Bavituximab, Pembrolizumab
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 19, 2026, 2:32 PM EDT
Completed Phase 1 Interventional

Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects

NCT01323062
View directory record Official record
Conditions
Non Small Cell Lung Cancer (NSCLC)
Interventions
Bavituximab
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Oct 19, 2026, 2:32 PM EDT
Completed Phase 2 Interventional

Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer

NCT01272791
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
bavituximab, Gemcitabine
Biological · Drug
Lead sponsor
Peregrine Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
15
States / cities
Chandler, Arizona • La Jolla, California • Boca Raton, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 19, 2026, 2:32 PM EDT
Completed Phase 1 Interventional

A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma

NCT01634685
View directory record Official record
Conditions
Rectal Adenocarcinoma
Interventions
Radiation, Bavituximab, Capecitabine
Radiation · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 19, 2026, 2:32 PM EDT
Terminated Phase 1 Interventional

A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients

NCT01984255
View directory record Official record
Conditions
Melanoma
Interventions
Arm A-Bavituximab 3mg/kg IV over 90 minutes weekly x 3 followed by Bavituximab 3mg/kg IV over 90 minutes weekly x 12 plus ipilimumab 3mg/kg IV, Arm B-Ipilimumab 3mg/kg IV over 90 minutes day 1 followed three weeks later by ipilimumab every 3 weeks x 3.
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 19, 2026, 2:32 PM EDT
Completed Phase 1 Interventional

Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer

NCT01288261
View directory record Official record
Conditions
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Male Breast Cancer, Recurrent Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
paclitaxel, bavituximab, laboratory biomarker analysis, pharmacological study
Drug · Biological · Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 21, 2016 · Synced Oct 19, 2026, 2:32 PM EDT
Completed Phase 3 Interventional

Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer

NCT01999673
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer Stage IIIB, Non-Small-Cell Lung Cancer Stage IV, Non-Small-Cell Lung Cancer Metastatic, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma, Nonsmall Cell Lung Cancer
Interventions
bavituximab, Docetaxel, Placebo (for bavituximab)
Biological · Drug · Other
Lead sponsor
Peregrine Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
39
States / cities
Huntsville, Alabama • Chandler, Arizona • Glendale, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 19, 2026, 2:32 PM EDT
Completed Phase 2 Interventional

Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer

NCT01138163
View directory record Official record
Conditions
Non-small-cell Lung Cancer
Interventions
Docetaxel plus bavituximab or placebo
Drug
Lead sponsor
Peregrine Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
24
States / cities
Chandler, Arizona • Campbell, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 19, 2026, 2:32 PM EDT
Completed Phase 2 Interventional

Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer

NCT01160601
View directory record Official record
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Interventions
Paclitaxel / Carboplatin, bavituximab
Drug
Lead sponsor
Peregrine Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
17
States / cities
Chandler, Arizona • Jonesboro, Arkansas • Whittier, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 19, 2026, 2:32 PM EDT
Terminated Phase 2 Interventional Results available

Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma

NCT05249569
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Axitinib, Avelumab, Bavituximab
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Oct 19, 2026, 2:32 PM EDT
Completed Phase 1 Interventional

Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection

NCT00128271
View directory record Official record
Conditions
Hepatitis C
Interventions
Bavituximab
Drug
Lead sponsor
Peregrine Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Bradenton, Florida
Source: ClinicalTrials.gov public record
Updated May 7, 2008 · Synced Oct 19, 2026, 2:32 PM EDT
Withdrawn Phase 1 Interventional

Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma

NCT02989870
View directory record Official record
Conditions
HepatoCellular Carcinoma, Unresectable HepatoCellular Carcinoma, Liver Cancer
Interventions
Stereotactic Body Radiation Therapy (SBRT), Sorafenib, Bavituximab
Radiation · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 5, 2020 · Synced Oct 19, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Results available

An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients

NCT04099641
View directory record Official record
Conditions
Gastric Cancer, GastroEsophageal Cancer
Interventions
Bavituximab, Pembrolizumab Injection
Drug
Lead sponsor
OncXerna Theraputics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
9
States / cities
New Haven, Connecticut • Weston, Florida • Columbus, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 19, 2026, 2:32 PM EDT
Completed Phase 1 Interventional

Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus

NCT00503347
View directory record Official record
Conditions
Hepatitis C Virus, Hiv Infections
Interventions
bavituximab
Drug
Lead sponsor
Peregrine Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
6
States / cities
Los Angeles, California • Newport Beach, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2011 · Synced Oct 19, 2026, 2:32 PM EDT
Completed Phase 1 Interventional

Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies

NCT00129337
View directory record Official record
Conditions
Tumors
Interventions
Bavituximab
Drug
Lead sponsor
Peregrine Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
6
States / cities
Tucson, Arizona • Santa Monica, California • Memphis, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Oct 19, 2026, 2:32 PM EDT